Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits

In Vivo

Volumn 19, Issue 3, 2005, Pages 515-522

  Puhakka, Hanna L ^a   Turunen, Päivi ^a   Gruchala, Marcin ^a   Bursill, Christine ^c   Heikura, Tommi ^a   Vajanto, Ismo ^a   Greaves, David R ^d   Channon, Keith ^c   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Adenovirus; Gene therapy; Inflammation; Vein graft stenosis

Indexed keywords

ADENOVIRUS VECTOR; BETA CHEMOKINE; BETA GALACTOSIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; VIRUS ANTIINFLAMMATORY PROTEIN 35K; VIRUS PROTEIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BYPASS SURGERY; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; GENE EXPRESSION; GENE TRANSFER; GRAFT OCCLUSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTIMA; MACROPHAGE; MALE; MORPHOMETRICS; NONHUMAN; RABBIT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STUDENT T TEST; TRANSGENE; VACCINIA VIRUS; VEIN GRAFT; VEIN GRAFT DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 17644419062     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Motwani JG and Topol EJ: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97(9): 916-931, 1998.
2. Ku DD, Caulfield JB, and Kirklin JK: Endothelium-dependent responses in long-term human coronary artery bypass grafts. Circulation 83(2): 402-411, 1991.
3. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD and Burton JR: Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 28(3): 616-626, 1996.
4. Ylä-Herttuala S and Martin JF: Cardiovascular gene therapy. Lancet 355: 213-222, 2000.
5. Seet BT, Singh R, Paavola C, Lau EK, Handel TM and McFadden G: Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor. Proc Natl Acad Sci USA 98(16): 9008-9013, 2001.
6. Bursill CA, Cai S, Channon KM and Greaves DR: Adenoviral-mediated delivery of a viral chemokine binding protein blocks CC-chemokine activity in vitro and in vivo. Immunobiology 207(3): 187-196, 2003.
7. Dollery CM, McEwan JR and Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 77(5): 863-898, 1995.
8. George SJ: Tissue inhibitors of metalloproteinases and metallo-proteinases in atherosclerosis. Curr Opin Lipidol 9(5): 413-423, 1998.
9. Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res 90: 251-262, 2002.
10. George SJ, Johnson JL, Angelini GD, Newby AC and Baker AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 9(6): 867-877, 1998.
11. Dollery CM, Humphries SE, McClelland A, Latchman DS and McEwan JR: Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 99(24): 3199-3205, 1999.
12. Turunen MP, Puhakka HL, Koponen JY, Hiltunen MO, Rutanen J, Leppanen O, Turunen AM, Narvanen A, Newby AC, Baker AH and Yla-Herttuala S: Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer. Mol Ther 6(3): 306-312, 2002.
13. Baker AH, Zaltsman AB, George SJ and Newby AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101(6): 1478-1487, 1998.
14. Baker AH, Wilkinson GW, Hembry RM, Murphy G and Newby AC: Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. Matrix Biol 15(6): 383-395, 1996.
15. Laitinen M, Mäkinen K, Manninen H, Matsi P, Kossila M, Agrawal RS, Pakkanen T, Luoma JS, Viita H, Hartikainen J, Alhava E, Laakso M and Ylä-Herttuala S: Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. Hum Gene Ther 9(10): 1481-1486, 1998.
16. Channon KM, Fulton GJ, Gray JL, Annex BH, Shetty GA, Blazing MA, Peters KG, Hagen PO and George SE: Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res 35(3): 505-513, 1997.
17. Leppanen O, Rutanen J, Hiltunen MO, Rissanen TT, Turunen MP, Sjoblom T, Bruggen J, Backstrom G, Carlsson M, Buchdunger E, Bergqvist D, Alitalo & Heldin CH, Ostman A and Yla-Herttuala S: Oral imatinib mesylate (STI571/Gleevec) improves the efficacy of local intravascular vascular endothelial growth factor-C gene transfer in reducing neointimal growth in hypercholesterolemic rabbits. Circulation 109(9): 1140-1146, 2004.
18. Pulkkanen KJ, Laukkanen JM, Fuxe J, Kettunen MI, Rehn M, Kannasto JM, Parkkinen JJ, Kauppinen RA, Pettersson RF and Yla-Herttuala S: The combination of HSV-Tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther 9(11): 908-916, 2002.
19. Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, Laukkanen J, Niemi M, Kossila M, Hakkinen TP, Kivela A, Enholm B, Mansukoski H, Turunen AM, Alitalo K and Yla-Herttuala S: Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 102(18): 2262-2268, 2000.
20. Ehsan A, Mann MJ, Dell'Acqua G and Dzau VJ: Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121(4): 714-722, 2001.
21. Chen SJ, Wilson JM and Muller DW: Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 89(5): 1922-1928, 1994.
22. Bai H, Morishita R, Kida I, Yamakawa T, Zhang W, Aoki M, Matsushita H, Noda A, Nagai R, Kaneda Y, Higaki J, Ogihara T, Sawa Y and Matsuda H: Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther 5(6): 761-769, 1998.
23. George SJ, Baker AH, Angelini GD and Newby AC: Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther 5(11): 1552-1560, 1998.
24. George SJ, Lloyd CT, Angelini GD, Newby AC and Baker AH: Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101(3): 296-304, 2000.
25. Cable DG, Obrien T, Schaff HV and Pompili VJ: Recombinant endothelial nitric oxide synthase transduced human saphenous veins: gene therapy to augment nitric oxide production in bypass conduits. Circulation 96(9:Suppl): 173-178, 1997.
26. Eslami MH, Gangadharan SP, Belkin M, Donaldson MC, Whittemore AD and Conte MS: Monocyte adhesion to human vein grafts: a marker for occult intraoperative injury? J Vasc Surg 34(5): 923-929, 2001.
27. Stark VK, Hoch JR, Warner TF and Hullett DA: Monocyte chemotactic protein-1 expression is associated with the development of vein graft intimal hyperplasia. Arterioscler Thromb Vasc Biol 17(8) 1614-1621, 1997.
28. Bursill CA, Choudhury RP, Ali Z, Greaves DR and Channon KM: Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 110(16): 2460-2466, 2004.
29. Beohar N, Flaherty JD, Davidson CJ, Maynard RC, Robbins JD, Shah AP, Choi JW, MacDonald LA, Jorgensen JP, Pinto JV, Chandra S, Klaus HM, Wang NC, Harris KR, Decker R and Bonow RO: Antirestenotic effects of a locally delivered caspase inhibitor in a balloon injury model. Circulation 109(1): 108-113, 2004.